Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Mile High Compounds LLC

Has Mile High Compounds LLC received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026 concerning products containing semaglutide and tirzepatide and retatrutide.

Letter facts

Letter date
March 31, 2026 (2026-03-31)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Online / Internet Pharmacy
Products named
GLP-1 SMGLP-2 TRZGLP-3 RTBAC Water
Violation categories
Unapproved new drug

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Factual Violation Summary

FDA determined the products are unapproved new drugs intended for human use despite research-only labeling, and their introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.

Statutory Citations & Specific Allegations

  • unapproved new drug
  • introduction or delivery for introduction into interstate commerce

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.